Advances in Hematology / 2017 / Article / Tab 4

Research Article

Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy

Table 4

Decreasing and nondecreasing total chimerism between day 30 and day 100.

Decreasing (%)Nondecreasing (%) value

FluBu4 with no PK18 (52.9)16 (47.1).04
FluBu4 with PK5 (23.8)16 (76.2)
BuCy6 (26.1)17 (73.9)

Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; PK, pharmacokinetics.